CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
- Live video webcast on Tuesday, August 19th at 2:40 PM ET HOUSTON, TX / ACCESS Newswire / August 14,...
Brain
Hemostemix’s Expands its Marketing Team Focused on Sales in Florida
Calgary, Alberta--(Newsfile Corp. - August 14, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous stem cell...
Last patient visit completed on schedule in Phase 1b clinical trial of HER-096 for Parkinson’s disease
Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300...
Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights
Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its...
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability
WESTBROOK, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health...
Cassava Reports Q2 2025 Financials Results and Provides Business Update
Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the...
Parents Urged to Make Kids’ Bedtime Screen-Free as National Campaign Launches with NYC Flash Mob
"Screen-Free Sleep" movement takes to the streets to address America's youth sleep crisis NEW YORK, Aug. 14, 2025 /PRNewswire/ --...
Moleculin Reports Second Quarter 2025 Financial Results and Highlights
- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial- 20+ additional clinical sites in...
Moleculin Reports Second Quarter 2025 Financial Results and Highlights
- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial- 20+ additional clinical sites in...
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE...
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE...
Native Hydrate Reviews: Don’t Buy Until You’ve Read This!
NEW YORK, NY / ACCESS Newswire / August 12, 2025 / Forget everything you thought you knew about staying hydrated...
Hemostemix Contracts Empire Market Ventures to Increase Market Awareness
Calgary, Alberta--(Newsfile Corp. - August 12, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it...
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
Hypha Labs Expands List of Functional Mushrooms Able to be Produced in its Revolutionary Mushroom Accelerator
Simple, In-Home Eight Day Cycle Generates Significant Yields of The World's Most Popular Mushroom Strains LAS VEGAS, NV / ACCESS...
Oragenics Q2 2025 Shareholder Update
Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics,...
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented...
ArriVent BioPharma Reports Second Quarter 2025 Financial Results
Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected...
Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical...